All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), the GvHD hub was pleased to speak to Zinaida Peric, University of Zagreb, Zagreb, HR. We asked, What do you think are the most promising new drugs in the treatment of steroid-refractory cGvHD?
What do you think are the most promising new drugs in the treatment of steroid-refractory cGvHD?
In this video, Peric discusses the advances in new oral agents, belumosudil and ruxolitinib, for the treatment of steroid-refractory chronic graft-versus-host disease. She also mentions the earlier drug, ibrutinib.
Your opinion matters
EHA 2019 | Clinical practice in chronic GvHD
Zinaida Peric from the University of Zagreb School of Medicine, Zagreb, HR, outlines the need for a multidisciplinary approach to chronic GvHD (cGVHD) management.
Clinical features of cGvHD following cord blood infused haploidentical transplantation
An open-label, non-randomized study found the immunomodulatory effects of cellular components in the umbillical cord were unique, but that further study was...
Subscribe to get the best content related to GvHD delivered to your inbox